After developing severe esophagitis and being prescribed life-long medications, Jimmy Minhas, a doctor and founder of GerdLi, researched and created the world's first natural supplement to relieve heartburn and acid reflux.
Physician-engineered GerdLi is the natural answer for people who live with acid reflux and heartburn. It's a premium-formulated antacid that maintains gut health and allows one to get back to eating the foods one loves. For those who hate to swallow pills, GerdLi comes as a small, easy-to-swallow capsule.
People that suffer from gastroesophageal reflux disease (GERD) are left to take prescription medications and must reduce or eliminate eating spicy foods, acrid vegetables, fatty, fried foods, fruit juices, wine, coffee and soda. Even large meals or eating before bedtime can cause uncomfortable acid reflux symptoms and, at times, damage to the esophagus.
GerdLi contains D-limonene, derived from the rinds of citrus fruits such as oranges, mandarins, lemons, limes and grapefruits and works in several ways to help with GERD.
D-limonene decreases stomach acid
It relieves symptoms of GERD, including indigestion, sour taste, regurgitation and bloating
GerdLi is made with non-GMO ingredients, is vegan, gluten-free and has no artificial flavors or fillers
"So many products on the market aiming to combat GERD and acid reflux, but GerdLi is by far the best remedy I've used. GerdLi offers great relief and the fact that it's created by doctors makes it stand out even more." MK, Happy Customer
GerdLi was developed over three years, and after three months of trials and testing, half the participants found improvement in their GERD symptoms. GerdLi may work as soon as one week and averages 2-4 weeks for relief of acid reflux symptoms. One study showed 72% of the participants experienced improvement within the 2-4 week period.
Although GerdLi is proven to alleviate heartburn and symptoms of GERD, lifestyle changes are just as crucial to a successful acid reflux regimen. GerdLi is meant to complement healthy lifestyle habits allowing patients to choose a natural way to relieve acid reflux and heartburn. Improved health includes staying active, eating clean foods and staying hydrated by drinking lots of water throughout the day.
GerdLi is manufactured in a special FDA-registered facility, ensuring it's a safe supplement made with the highest quality ingredients. High-potency D-limonene is carefully sourced to be sure each bottle of GerdLi delivers the most effective results for reducing acid reflux. It works as an alkaline in the stomach to reduce acid, and its name is derived from lemon rinds, which have the highest concentration of limonene.
Once D-limonene is taken, it's rapidly absorbed in the gastrointestinal tract and distributed into tissue. GerdLi reduces heartburn and reflux symptoms and may help some people reduce the amount of prescription medication they take.
The mission at GerdLi is to help people suffering from acid reflux while offering them an alternative to prescription medications that often cause side effects. GerdLi also cares about creating a healthier world, donating part of its proceeds to support the Esophageal Cancer Society.
Contact Information:
Matt Kane
Media manager [email protected]
680 850 3345
iQuanti: Deciding where to borrow money from in a time of need can be a hassle when it matters most. But luckily, there are many options to consider, including a line of credit and a loan. Knowing the options you have can help you decide which is right for you when the time comes. For a better understanding of a life of credit vs. loan, here is everything you need to know.
What is a line of credit?
A line of credit can come in many forms, including a credit card or equity line from an investment like your home. With a line of credit, you can borrow as much as you need so long as it falls under the credit limit. When it comes time to pay the amount back, there are generally more flexible guidelines you can follow, such as no hard deadline to repay the borrowed amount and varying interest rates. Types of credit lines include:
Revolving credit
Installment credit
Secured or unsecured credit
What is a loan?
A loan, on the other hand, is a more rigid lending option. When you apply for and take out a loan, you agree to the terms upfront, including the loan amount, the date you need to pay the loan back, the minimum monthly payment, and any other important details. You are then obligated to repay the loan according to the terms and may not have much flexibility outside of that initial agreement. It's also important to mention that there are numerous types of loans, including:
Cash advances
Personal loans
Mortgages
Business loans
Line of credit vs. loan
So when should you choose a line of credit or a loan? It depends on your needs. Remember, not all lines of credit or loans are created equal. Here are some instances when each option may make sense:
When to choose a line of credit
When you're not sure how much money you'll need or want flexible access to funds, a line of credit is the way to go. While there are more variations, the flexibility of the credit can help you to fund the things you need. Not to mention, if the cost is not set in stone, you can access more of that credit as needed.
When to choose a loan
Loans can work well for planned one-time large purchases. Because they're predictable, like the purchase, these are easier to manage as you repay with set terms to follow. Examples of when a personal loan may be perfect include: furniture or appliance purchases, home repairs, moving expenses, and paying down other debts.
The bottom line
Both loans and credit lines are great tools for helping to afford expenses, both unexpected and planned. While you may have access to both, the choice should come down to the flexibility you need, the repayment terms you want, and also, which options are readily available to you when you need them most.
Smile Digital Health, a leading FHIR® health data fabric and exchange solutions provider, announced today that it has acquired Alphora, a market leader in Clinical Quality Language (CQL) that provides tooling and services to unlock clinical reasoning, decision support and other quality metrics capabilities. As a result of the acquisition, Smile Digital Health customers now have access to Smile Alphora, the company's new clinical reasoning capability that leverages its Fast Healthcare Interoperability Resources (FHIR) expertise to quickly and accurately generate insights that efficiently improve patient outcomes. Powered by the world's most advanced health data fabric, Smile Alphora is the first major expansion under the company's new Smile Digital Health umbrella and, along with the company's Smile CDR platform, exemplifies its broad expertise and capabilities.
"Clinical reasoning integrated with the health data fabric will bring pivotal capabilities to our clients. Event-driven analysis supports quality measures, clinical decisions, order sets and a broad range of practice guidelines which will drive efficiencies and process improvements for all healthcare organizations," said Duncan Weatherston, Chief Executive Officer, Smile Digital Health. "We are delighted to have such an amazing team of innovators join us through our acquisition of Alphora. Together, we will help transform the landscape of information-driven healthcare."
The new Smile Alphora offering will bring added, advantageous capabilities to Smile Digital Health, including a high-performance measure evaluation platform for quality measurement and reporting, a standards-based clinical reasoning engine, complete FHIR and CQL-based measure specifications for evaluating clinical quality, and more. The added CQL capabilities brought by Alphora will aid decision support and decision analysis, expanding Smile Digital Health's ability to effectively make healthcare more efficient and expedited.
"Smile Alphora, the culmination of our long-standing relationship with Alphora indicates a leap forward in open standards and health information technology as it brings together a best-in-class group of people and marries the collection and analysis of data with the application of that data to create a direct and tangible health outcome for patients," said James Agnew, Chief Technology Officer, Smile Digital Health. "The expertise that Alphora brings in deriving knowledge from clinical data will allow Smile Digital Health's customers to extract additional insights and actionable details from their data, unleashing the power of near real-time healthcare quality metrics."
"We believe in the availability of high-quality clinical practice guidelines and recommendations to all peoples. Clinical reasoning and the dynamic delivery of content is how that gets done. Smile Digital Health is the platform where the belief becomes a reality," said Rob Reynolds, Director of Product, Smile Digital Health.
Over the coming year, Smile Digital Health plans to continue its advancements in end-to-end interoperability with expanded offerings that greatly enhance the breadth of its data fabric solutions by helping customers meet current interoperability goals and innovate to prepare for future digital transformations.
About Smile Digital Health
Smile Digital Health is a health information technology company focused on delivering better global health through open standards. Our enterprise-grade, open framework data fabric and integration platform fuels healthcare's digital transformation and accelerates value creation across all patient journeys at scale. Powered by our HL7® FHIR® standard-based clinical data repository (#SmileInside), our platform enables collaboration and allows organizations to ingest, transform, store, enrich, analyze, aggregate and meaningfully share the health information to power digital transformation. We prepare healthcare providers, payers, researchers and life sciences organizations for a connected future beyond legacy systems, adding new value through intelligent use of information and ultimately delivering better patient outcomes. For more information visit: SmileDigitalHealth.com.
Contact Information:
Lucy Railton
Director of Marketing [email protected]
(800) 683-1318
SURREY, British Columbia - November 1, 2022 - (Newswire.com)
A clinical research study has shown that facial topical cream promotes facemask tolerability and compliance during the COVID-19 pandemic. The reputable research was led and authored by Dr. Olumuyiwa Bamgbade at the Salem Anaesthesia Pain Clinic in Surrey, British Columbia, Canada.
Facemask use is associated with localized facial skin complications such as rash, bruising, acne, itching, discomfort, discoloration, redness, hotness, ulceration, crusting, infection, and dermatitis. Such complications may provoke face-touching, face-scratching and facemask non-compliance, which undermines facemask protective efficacy and COVID-19 infection control. Therefore, the research study examined the impact of different non-prescription topical creams on facemask tolerability, facemask compliance and related skin complications during the COVID-19 pandemic. Six topical creams were evaluated including petrolatum jelly, hydrocortisone cream, lidocaine gel, zinc oxide cream, arnica cream and diphenhydramine cream.
"The study revealed that all the topical creams reduce facemask-related facial redness, facial temperature rise, and facial pain. Facial temperature rise is lowest with topical lidocaine gel; early facial redness is lowest with topical hydrocortisone or diphenhydramine cream; severe facial redness is lowest with topical hydrocortisone or zinc oxide cream; and facemask-related pain is lowest with topical lidocaine gel," explained Dr. Bamgbade. "All the topical creams reduce facemask-related skin complications, and thereby enhance facemask compliance and tolerability. Facemask compliance is best with topical lidocaine gel. Topical petrolatum jelly has the best user satisfaction and odor rating. People who wear facemasks frequently or for prolonged duration should protect their skin with topical petrolatum, zinc oxide or arnica cream. People who experience facial redness from facemasks should treat their skin with topical hydrocortisone or diphenhydramine cream," advised Dr. Bamgbade. "People who experience significant facemask-related facial pain may use topical lidocaine gel."
Based in Surrey, British Columbia, Canada, Salem Anaesthesia Pain Clinic is a specialist pain clinic and research center that provides multimodal pain management, interventional pain treatment, substance misuse therapy, insomnia treatment and preoperative optimization therapy. Dr. Olumuyiwa Bamgbade is an anesthesiologist, a specialist pain physician and the director of the Salem Pain Clinic. Visit https://salempainclinic.net/. For further information: [email protected].
Leading podiatrist in Wayne, New Jersey, partners with the Ankle & Foot Centers of America, the nation's leading group of foot and ankle surgeons. This relationship allows doctors to dedicate their time to treating patients instead of administrating a podiatry practice.
Renown New Jersey podiatrist Lindsey Calligaro, DPM, of Wayne Foot & Ankle Center has recently teamed with Ankle & Foot Centers of America, the market leader in physician practice management and process improvement, to better serve patients. Wayne Foot & Ankle Center has been providing the highest-quality care to patients for over 40 years, and is dedicated to improving the lives of people in the northern NJ community.
Dr. Lindsey Calligaro earned her Doctor of Podiatric Medicine from the New York College of Podiatric Medicine in 2011 and attended a comprehensive three (3) year residency in Scranton, Pennsylvania with Dr. Guido LaPorta. Dr. Calligaro served as Chief Fellow during her fellowship in Baltimore, Maryland, at the Rubin Institute for Advanced Orthopedics/International Center for Limb Lengthening. Dr. Calligaro's training specialized in complex foot and ankle deformity correction and pediatric deformity correction. Dr. Calligaro treats a variety of foot and ankle problems, including bunions, heel pain, trauma, and flatfeet. She also specializes in all aspects of pediatric foot and ankle deformity correction with a special interest in clubfoot. Helping to serve the needs of patients is what brought Dr. Calligaro to podiatry, and it is what motivates her to provide the best care possible every day.
Teaming with Ankle & Foot Centers of America allows physicians like Dr. Calligaro to do what they do best, take care of patients. With Ankle and Foot Centers of America, Dr. Calligaro is now able to benefit from the most advanced software, reporting, and office support in the industry. As healthcare becomes more complicated with technology and regulation, physicians must rely on expert support.
Incorporating the central scheduling team and call center from Ankle and Foot Centers of America allows patients to make appointments with greater ease with this Wayne, NJ, Podiatrist. Whether booking online or over the phone, patients can now expect to have a more streamlined experience. Additionally, Ankle and Foot Centers of America incorporates advanced network safeguards to better protect patient data and provides new training for staff on the latest advances and changes in healthcare.
With a shared commitment to excellence and dedication to patient well-being, Dr. Calligaro and the team at Ankle and Foot Centers of America look forward to treating the foot and ankle needs of patients in north New Jersey.
About Ankle & Foot Centers of America - Founded in Atlanta over 30 years ago, Ankle & Foot Centers of America is dedicated to providing patients with top-tier service and support through best-in-class technology and processes so that physicians can optimize patient outcomes and satisfaction.
A limited number of one- and two-bedroom Assisted Living apartments are available for rent at The Carolina Inn. Residents welcome being a part of the popular Village Green neighborhood, which boasts mature trees, rolling hills, water vistas, and a peaceful setting. The Carolina Inn also is less than one mile from Cape Fear Valley Medical Center and about 15 minutes from Fort Bragg and the PX.
FAYETTEVILLE, N.C. - November 1, 2022 - (Newswire.com)
Since 1983, November has been recognized as national Alzheimer's Disease Awareness Month, which makes this month the perfect time to bring attention to memory loss issues that affect millions of seniors each year.
According to the Alzheimer's Association, approximately 6.5 million Americans are living with Alzheimer's disease. It is the most common form of dementia, accounting for 60 to 80 percent of diagnosed cases, but it is not the only type of memory loss. Nearly one in nine seniors over age 65 in the United States have dementia while an additional 22 percent have mild cognitive impairment. Percentages rise with age, from approximately three percent of those between 65 and 69 to 35 percent of those aged 90 and older.
During early stages, Alzheimer's disease may resemble memory issues that are typical of aging. In later stages, however, the disease can greatly impact a person's ability to perform everyday tasks. Eventually, a person experiencing memory loss in any form may require one-on-one attention to function on a daily basis. At that point, finding an Assisted Living community that offers memory support is often the best care option. The Carolina Inn Assisted Living in Fayetteville's Village Green neighborhood provides person-centered care for seniors in the Sandhills region and Moore County who need mild memory support and want to stay close to the area they know.
Offering a thoughtful and protected environment, The Carolina Inn has 24-hour security and is located within a gated neighborhood, which is important since many people with dementia tend to wander. The Carolina Inn also has the highest nurse-to-resident ratio for Assisting Living communities in the area with nurses on each floor. Compassionate staff provide around-the-clock care as needed and health services including medication management and monitoring along with first aid.
Residents are encouraged to participate in Life Enrichment programs to keep their minds and bodies engaged and help them maintain a full and meaningful life. Musical experiences are especially beneficial to memory support and often give those who are struggling to communicate verbally a way to express themselves. Activities like sing-a-longs, musical performances from well-known local and professional artists, Name The Tune games, and more are on the calendar weekly at The Carolina Inn.
To learn more about Assisted Living and memory care support at The Carolina Inn, log onto www.CarolinaInnNC.com or call Angela Rabelos at (910) 501-2271 to schedule a tour.
Contact Information:
Debbie Szwast
Director of Account Services [email protected]
630-627-5200
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicologythat demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory properties may be useful in decreasing inflammation associated with a wide range of serious human disorders, and these Cannabis compounds potentially have more favorable side effect profiles than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which currently lead the anti-inflammatory market based on sales. Largely because of the increasing prevalence of chronic and auto-immune inflammatory disorders, the market for anti-inflammatory therapies is expected to grow to $191.42 billion by 2027.
"We believe that this is the first demonstration of the anti-inflammatory potential of some very potent minor cannabinoids and terpenes derived from Cannabis," said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. "The identification of cell type-specific immune modulating effects by different individual cannabinoids and terpenes was an important first step in designing our novel anti-inflammatory therapies. The results from our second study on the anti-inflammatory effects of proprietary mixtures of these ingredients will be published subsequently with our collaborators at Michigan State University and Chaminade University."
Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies. To determine whether these cannabinoids and terpenes could reduce inflammation, Gb Sciences' colleagues at Michigan State University tested the individual Cannabis constituents over a wide range of concentrations in human, primary immune cells in a co-culture system that mimics the complex interactions that regulate the human immune system. Three immune cell types were chosen as representatives within these native human immune cell mixtures based on their important roles in modulating the inflammatory cascade.
This study demonstrated that delta-9 tetrahydrocannabinol (THC) had the greatest effect on reducing inflammatory biomarkers and processes in all three immune cell types. Following THC, the greatest immune activity modulation was measured by cannabidivarin (CBDV), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and lastly, cannabidiol (CBD) in decreasing order based on the number of statistically significant changes measured in inflammatory bioassays relative to the control. Some of these minor cannabinoids and the terpenes tested had very 'selective' anti-inflammatory effects, which targeted a single cell type and/or caused a change in only a single inflammatory bioassay.
This study entitled "Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes" was co-authored by Gb Sciences' own President and Chief Science Officer, Andrea Small-Howard, and her collaborators Lance K. Blevins, Anthony P. Bach, Robert B. Crawford, Jiajun Zhou, Joseph E. Henriquez, Michael D. Rizzo, Sera Sermet, D.M. Isha Olive Khan, and Norbert Kaminski from Michigan State University (East Lansing, Michigan, USA) and Helen Turner from Chaminade University of Honolulu (Honolulu, Hawai'i, USA). The second part of this study measured the effects of proprietary mixtures of cannabinoids and terpenes on inflammation within this human, primary immune cell model, and this second study will be published next in collaboration with our colleagues at Michigan State University and Chaminade University.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome a new contract development and manufacturing organization, Quality Chemical Laboratories (QCL), to its growing client base.
Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings. For over 25 years, this leading CDMO has provided GMP-compliant formulation development and manufacturing services for the pharmaceutical industry. The company's clients range from small start-up companies to some of the most prominent pharmaceutical corporations in the world.
As its client base continues to grow, Quality Chemical Laboratories recognized the importance of implementing a new software system to enhance its processes while gaining efficiency and maintaining GMP and FDA compliance.
QCL's exhaustive search for a new software system led the company to the InstantGMP PRO system. While the software's all-in-one capabilities impressed the QCL team, they required computer system validation to determine if the system:
Achieves its intended purpose by meeting user requirements.
Is free from any installation or performance issues that could negatively impact the integrity of the CDMO's production cycles, raw materials or finished pharmaceutical products.
To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit. During the software vendor auditing process, QCL reviewed every piece of the software's validation documentation and standard operating procedures (SOPs) via a virtual session with InstantGMP to confirm that InstantGMP PRO:
Is properly validated.
Vendor documentation can be appropriately leveraged to save QCL significant time and resources.
Functions accordingly and accurately.
Aligns with the information defined in the provided user requirement documentation.
After QCL reviewed all the respective documentation and asked any pertinent questions, it created and supplied a detailed audit report that identified topics that required further discussion and some minor issues that needed to be resolved. At the conclusion of the audit process, InstantGMP successfully satisfied Quality Chemical Laboratories' requirements.
Not only did this process lead to a successful relationship, but it also provided the QCL team a better understanding of the software's full capabilities. Additionally, the audit process offered InstantGMP an opportunity to address previously unidentified issues and further enhance the software with new features that best meet manufacturers' needs.
InstantGMP is excited to provide Quality Chemical Laboratories with a validated all-in-one software system that truly meets its needs for improved processes and assured compliance. InstantGMP wishes them continued success in the contract formulation development and manufacturing industry and thanks them for helping InstantGMP enhance their software during the audit process.
ZetrOZ's sam®️ technology promotes soft tissue healing, helping patients return to work sooner and preventing more severe injuries; the only FDA-cleared home-use multi-hour ultrasound stimulator.
TRUMBULL, Conn. - October 31, 2022 - (Newswire.com)
ZetrOZ Systems presented to the Michigan Self-Insurers Association 2022 Fall Conference on Oct. 27 about how the ZetrOZ sam® wearable ultrasound device helps patients return to work more quickly after soft-tissue injuries and prevents more severe injuries from occurring.
ZetrOZ Systems has partnered with the organization of self-insured employers on ways to educate businesses on how to prevent and respond to workplace accidents and injuries. The sam® device has been shown in more than 30 clinical studies to deliver significant improvement in joint function, increased pain reduction, and improved vasodilation - all of which ultimately contribute to accelerated healing and increasing integrity of recovered soft tissue. The sam® product line is also shown to mitigate pain from soft-tissue injuries in the upper neck and back, shoulder conditions, and knee osteoarthritis.
"sam® is already helping thousands of lives daily, and we're honored to be partnering alongside MSIA and the self-insured businesses in Michigan to provide effective treatment for workplace injuries," said Dr. George Lewis, CEO of ZetrOZ Systems. "It's incredibly important to us to help treat workers' injuries, relieve pain, improve long-term outcomes, and ultimately, get people back to work sooner."
Statistics show a need for better care for the workforce, particularly at self-insured workplaces. American workers experienced 2.1 million injuries in 2020, according to the U.S. Bureau of Labor Statistics, and 82% of workers at large firms were covered by self-funded insurance plans in 2021.
There also is a need for effective pain relief without potentially addictive and dangerous medications. The United States spends about $1 trillion on opioid use disorder and fatal opioid overdoses (2018, Centers for Disease Control and Council of Economic Advisors). Innovations like the sam®x1 pain relief ultrasound device provide wireless, long-duration ultrasound therapy for injury healing and pain relief without medication.
The Michigan Self-Insurers' Association [MSIA] is a non-profit organization founded in 1952 that has worked tirelessly over the last 70 years to educate self-insured employers on workers' compensation issues. With the goal of reducing and ultimately preventing workplace accidents and injuries, MSIA and sam® are uniquely aligned to empower workers with the tools and resources to protect themselves and their livelihoods.
MSIA's Board of Managers includes DTE, Meijer, Marathon Oil, and representation from many other self-insured employers, and the organization has been a proud partner of Kids' Chance of Michigan since 2013.
"Our sam® product portfolio offers patients a way to mitigate and reduce workplace injury and pain without resorting to opioids or nonsteroidal anti-inflammatory drugs, which have shown to potentially harm more than they help. Now, these hard-working men and women have a chance to safely and properly heal in the comfort of their own homes," Lewis said.
ZetrOZ Systems is leading healing innovations in sports medicine and developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of sam®, a product line designed for the treatment of acute and chronic musculoskeletal conditions. To learn more, visit zetrozsystems.com.
It's hurricane season once again, and this year, parts of the U.S. were hit especially hard. Hurricanes have an effect on a wide variety of individuals and families. Current and former military members are some of those who this year's major storms have impacted.
There's some good news, though: debt relief for veterans affected by hurricanes is available. We will take some time right now to talk about the details of this program. We'll also discuss how recent hurricanes have harmed veterans and their families.
How Have the Recent Hurricanes Impacted Veterans?
There were two hurricanes this year that had a catastrophic impact on some veterans and their families. Fiona formed the second week of September of this year. It began as a Category 4 over the Atlantic Ocean and caused damage in several countries.
Ian originated in the third week of September and struck Florida as a Category 4. It was the most devastating hurricane to hit the state since 1935.
Many former service members call Florida home, so it's not surprising that a disproportionate number of those impacted were veterans. Some of them had their primary residences wiped out by Ian. Others had vehicles and various material possessions destroyed. Still, others were physically harmed by the hurricanes and had to pay for lengthy hospital stays.
What is the Debt Relief Program?
The hurricane debt relief program is aimed toward helping veterans who were directly impacted by recent hurricanes Fiona and Ian.
The VA, which is shorthand for the Department of Veteran Affairs, quickly took steps to implement debt relief for veterans that the two hurricanes we've mentioned impacted. The VA allows veterans and their families to suspend debt payments if they were affected by either of the two recent hurricanes.
What Debt Payments Can This Program Suspend?
The VA set up a website and phone number that veterans and their families who suffered losses due to this year's hurricanes can use. These individuals can suspend payments for medical care and pharmacy copayments. They can also defer payment on debts covering essentials like food and shelter.
Simply put, the program is intended to temporarily suspend the need for veterans and their families to pay back the VA for outstanding debts in the face of this pair of natural disasters. Any veterans or their families who wish to see whether they're eligible can contact the VA using either the phone number or website set up for this purpose.
This Program Can Help Vets Impacted by Hurricanes
The two hurricanes that caused so much havoc over the past few weeks are almost unprecedented. Nothing similar has happened to the state of Florida for nearly the past hundred years. It's likely that climate change is fueling larger and more unpredictable storm systems, and these types of weather events might become more commonplace as the years pass.
Veterans and their families who were directly impacted by hurricanes this year may have high medical bills. Others might be dealing with the loss of their homes, vehicles, possessions, and so forth.
The VA has made a phone number and website available that veterans and their relatives can use if they need relief from any outstanding debts they owe. It is not a long-term solution. However, it will provide some welcome short-term relief for individuals who served this country through military service, as well as their families.
Any vets who are interested should reach out to the VA. This entity exists to help out veterans in any way that it can. Debt relief is one way to ease economic hardship following a pair of violent weather events that rocked this country.
